Management and Prevention of Cardiovascular Disease in Metabolic Syndrome and Diabetes: Focus on PCSK9 Inhibitors


Thursday, December 1st, 2016

 6:00 pm – 7:30 pm

Hilton Universal City, Los Angeles 

555 Universal Hollywood Dr, Universal City, CA 91608

A satellite symposium, to be held in association with the 14th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
December 1-3, 2016 at the Hilton Universal City Hotel in Los Angeles, CA

Download the CME Brochure

How to Register

Cost – $75 includes refreshments
To Register for the CME Symposium only, please click here:
CME Symposium ONLY

FREE for 14th WCIRDC Attendees
If you are already registered for the WCIRDC, you can
email at  to pre-register OR
Pre-Register here: Registration for WCIRDC Attendee

To register for the entire 14th WCIRDC and CME Symposium
Please click here:

Program Format

The program will intersperse panel discussions with didactic lectures, leaving time for Q +A and Audience participation throughout  the activity

Program Description

Due to a high residual risk for CVD despite treatment with statins, there is a growing interest in having non-HDL cholesterol as the target of lipid management in the prevention and treatment of CVD. This symposium focuses on further reduction of LDL-cholesterol as well as other lipid components like Lp(a). Despite the availability of numerous clinical guidelines for the management of lipids to reduce CVD risk, appropriate application of these guidelines remains low, likely contributing to CVD morbidity and mortality. The overall objective of this CME program is to examine the prevalence of CVD in high-risk patients, discuss appropriate guidelines, provide an update on pharmacological strategies to reduce CVD risk, and offer expert insights into how to apply the lipid management guidelines and applicable treatment target goals to achieve better patient outcomes.


Symposium Agenda

View Faculty

6:00 pm | Welcome & Introduction —Yehuda Handelsman, MD, Chair
6:05 pm | Epidemiology and Pathophysiology of CVD in the High-Risk People with Obesity, Metabolic syndrome and Diabetes — Zachary T. Bloomgarden, MD
6:25 pm | PCSK9 Physiology in Lipid Disorders, From Genetics to Discovery- Role in Cardiovascular Disease- Sergio Fazio, MD, PhD
6:45 pm | The Development, Efficacy and Safety of the Monoclonal Antibodies PCSK9 Inhibitors — Evan Stein, MD, PhD
7:05 pm | Panel Discussion, Q & A: Beyond Statins- the Potential Position of PCSK9 Inhibitors in the Treatment Algorithm
Faculty:  Zachary T. Bloomgarden, MD ; Sergio Fazio, MD, PhD ; Evan Stein, MD, PhD; Robert J. Chilton, DO; Nikolaus Marx, MD
Moderator:  Yehuda Handelsman, MD
7:25 pm | Adjourn


Learning Objectives:

  • Describe the unmet need for additional lipid modifying agents, specifically the LDL-lowering therapies, beyond current available statin-based management, to reach adequate goals in the high-risk patient with diabetes.
  • Discuss the new understanding of the mechanisms that lead to the development of cardiovascular disease, including the role of PCSK9 in LDL-C homeostasis.
  • Explain emerging options for the management of lipid disorders to prevent and treat cardiovascular disease in high-risk patients with obesity and diabetes, targeting non HDL-C, focusing on LDL, TGL and Lp(a).
  • Discuss the mechanisms, efficacy and safety of the monoclonal antibodies PCSK9 inhibitors with insight into potential impacts on future clinical practice as a combination therapy with statins, and as monotherapy.
  • Compare and evaluate evidence from recent clinical trials on novel agents in clinical development and be aware of other lipid modifying agents in ongoing cardiovascular outcome trials.

Target Audience:

This educational initiative is designed for endocrinologists, cardiologists, family physicians, internists, diabetologists, nurse practitioners, and other health care professionals interested in diabetes and obesity.

Accreditation Information:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the accreditation council for Continuing Medical Education through the joint providership of PESI, Inc and Metabolic Endocrine Education Foundation (MEEF). PESI, Inc is accredited by the ACCME to provide continuing medical education for physicians. The PESI, Inc designated this live educational activity for a maximum of 1.5 AM PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

This is a CME Program Supported by an Educational Grant from Amgen

For information please contact: or (818)342-1889